Home Companies Catalysts Deep Dives
Izervay avacincaptad pegol APPROVED
Drug Profile
ModalityPegylated aptamer
RouteIntravitreal
Therapy AreaOphthalmology
Launch2023-08-04
US LOE2038-08-01
Peak Sales Est$2500M
Formulations[{"id":"izervay-ivt","route":"Intravitreal","setting":"HCP_ADMINISTERED","frequency":"Monthly","is_p
Companies
ALPMY (ORIGINATOR)100%
Mechanism: C5 inhibitor (pegylated aptamer)
Expert: Pegylated RNA aptamer inhibiting complement C5 for geographic atrophy.
Everyday: Blocks complement protein C5 to slow progression of eye disease.
Targets: ["C5"]
Revenue History
PeriodRevenue ($M)
FY2024$389M
H1 FY2025$227M
Programs (1)
IndicationStageKey StudyRegional Status
Geographic atrophy secondary to AMDAPPROVEDGATHER1/GATHER2[{"stage":"APPROVED","region":"US","approval_date":"2023-08-04"}]
Notes
Geographic atrophy treatment. Competes with Apellis Syfovre. Label expansion Feb 2025.
Data from Supabase · Updated 2026-03-24